141 related articles for article (PubMed ID: 11535320)
1. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors.
Jackson LA; Austin G; Chen RT; Stout R; DeStefano F; Gorse GJ; Newman FK; Yu O; Weniger BG;
Vaccine; 2001 Sep; 19(32):4703-9. PubMed ID: 11535320
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
Simon JK; Carter M; Pasetti MF; Sztein MB; Kotloff KL; Weniger BG; Campbell JD; Levine MM
Vaccine; 2011 Nov; 29(51):9544-50. PubMed ID: 21986218
[TBL] [Abstract][Full Text] [Related]
3. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial.
McAllister L; Anderson J; Werth K; Cho I; Copeland K; Le Cam Bouveret N; Plant D; Mendelman PM; Cobb DK
Lancet; 2014 Aug; 384(9944):674-81. PubMed ID: 24881803
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.
Mitchell DK; Ruben FL; Gravenstein S
Pediatr Infect Dis J; 2005 Oct; 24(10):925-7. PubMed ID: 16220095
[TBL] [Abstract][Full Text] [Related]
5. Dose sparing with intradermal injection of influenza vaccine.
Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
Greenberg DP; Robertson CA; Talbot HK; Decker MD
Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
[TBL] [Abstract][Full Text] [Related]
8. Needle-free delivery of influenza vaccine using the Med-Jet® H4 is efficient and elicits the same humoral and cellular responses as standard IM injection: A randomized trial.
Shapiro JR; Hodgins B; Hendin HE; Patel A; Menassa K; Menassa C; Menassa M; Pereira JA; Ward BJ
Vaccine; 2019 Feb; 37(10):1332-1339. PubMed ID: 30709725
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
Fernando GJP; Hickling J; Jayashi Flores CM; Griffin P; Anderson CD; Skinner SR; Davies C; Witham K; Pryor M; Bodle J; Rockman S; Frazer IH; Forster AH
Vaccine; 2018 Jun; 36(26):3779-3788. PubMed ID: 29779922
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
Squarcione S; Sgricia S; Biasio LR; Perinetti E
Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
[TBL] [Abstract][Full Text] [Related]
13. [An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season].
Lupulescu E; Ioniţă E; Botez D; Matepciuc M; Tabra ME; Tecu C; Alexandrescu V; Munţiu A
Bacteriol Virusol Parazitol Epidemiol; 1997; 42(1-2):110-2. PubMed ID: 9235136
[No Abstract] [Full Text] [Related]
14. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
15. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
16. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
Carter C; Houser KV; Yamshchikov GV; Bellamy AR; May J; Enama ME; Sarwar U; Larkin B; Bailer RT; Koup R; Chen GL; Patel SM; Winokur P; Belshe R; Dekker CL; Graham BS; Ledgerwood JE;
PLoS One; 2019; 14(9):e0222178. PubMed ID: 31532789
[TBL] [Abstract][Full Text] [Related]
18. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
van de Witte S; Nauta J; Montomoli E; Weckx J
Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
[TBL] [Abstract][Full Text] [Related]
19. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ
Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial.
Song JY; Cheong HJ; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Noh JY; Choi WS; Kim H; Kim KH; Kim WJ
Vaccine; 2015 Oct; 33(41):5437-5444. PubMed ID: 26314625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
